<DOC>
	<DOCNO>NCT02140346</DOCNO>
	<brief_summary>RV1729 new medicine develop potential treatment asthma smoke related lung disease ( also know chronic obstructive pulmonary disease - COPD ) . The objective study investigate safety , tolerability , pharmacokinetics pharmacodynamics repeat dos RV1729 patient COPD 28 day .</brief_summary>
	<brief_title>A Study Investigate Safety , Tolerability , Pharmacokinetics Pharmacodynamics Repeat Doses RV1729 28 Days Patients With COPD</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Sign inform consent document indicate understand purpose procedure require study willing participate study . Be man woman nonchildbearing potential age 40 75 year Women nonchildbearing potential must either amenorrhoeic &gt; 1 year appropriate clinical profile permanently sterilise Women must agree donate egg ( ovum , oocytes ) Screening least 6 month final dose study medication Men must willing use one form contraception ( documented failure rate le 1 % ) agree donate sperm Screening 90 day post last dose study agent Chronic obstructive pulmonary disease diagnosis symptom compatible COPD least 1 year Screening . Severity disease : subject conform current severity classification Global Initiative Chronic Obstructive Lung Disease ( GOLD , 2014 ) Grade II/III On background therapy inhale steroid without addition longacting bronchodilator ( either longacting beta agonist [ LABAs ] longacting muscarinic antagonist [ LAMAs ] ) . Be able produce acceptable induced sputum sample Screening visit . Capable comply study restriction procedure include ability use study inhaler correctly . A current previous smoker smoke history â‰¥10 pack year . Have 12 lead ECG record consistent normal cardiac function Screening visit predose Day 1 A history lifethreatening COPD include respiratory arrest , intensive care unit admission and/or require intubation . A history one hospitalisation COPD 2 year Screening . Evidence cor pulmonale , clinically significant pulmonary hypertension chronic use oxygen . Upper low respiratory tract infection , include exacerbation COPD , require augmentation therapy within 6 week Screening . Other respiratory disorder : subject history asthma , active tuberculosis , lung cancer , bronchiectasis , sarcoidosis , lung fibrosis chronic pulmonary disease . A chest Xray Screening ( within 6 month prior Screening visit ) show abnormality , opinion Investigator clinically significant unrelated COPD . A history chronic disease include , limited , unstable uncontrolled hypertension ( diagnose hypertension 6 month Screening ) , sleep apnoea , cardiovascular , endocrine , neurological , hepatic , gastrointestinal , renal , haematological , urological , immunological ophthalmic disease Investigator believe clinically significant e.g. , unstable could impact subject safety participation study . Previous lung resection lung reduction surgery . Vital sign assessment outside follow range : inclusion blood pressure ( subject supine 10 minute ) must 100 160 mmHg systolic , inclusive , 55 100 mmHg diastolic ; heart rate must 40100 bpm . These criterion must meet Screening , Day 1 predose Day 1 . Have clinical abnormality laboratory parameter outside reference range Screening Day 1 . Liver function test result ( ALT , aspartate amino transferase gamma glutamyl transferase ) &gt; 2 x ULN ( upper limit normal ) Screening Day 1 . Chronic liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . Positive test human immunodeficiency virus ( HIV ) 1 2 antibody , hepatitis B virus ( HBV ) infection hepatitis C antibody . Unable unwilling undergo multiple venepuncture procedure subject poor access vein suitable cannulation . If woman , positive serum pregnancy test Screening . Definite suspect history drug alcohol abuse within previous 5 year . Positive test alcohol drug abuse , include cannabinoids , alcohol , opiates , cocaine , amphetamine , benzodiazepine barbiturate Screening Day 1 Day 1 . History regular alcohol consumption within 6 month study define average weekly intake &gt; 21 unit male , &gt; 14 unit female . History clinically significant allergy , opinion Investigator would contraindicate participation . Known allergy study drug excipients formulation previously expose RV1729 . Donated blood blood product substantial loss blood ( 500 mL ) within 3 month first administration study drug intention donate blood blood product study . Received experimental drug use experimental medical device within 3 month within period less five time drug 's halflife , whichever longer , first dose study drug schedule . Requires routine treatment COPD use one ( ) therapy list protocol within 6 week Screening . A disclosed history one know Investigator , significant noncompliance previous investigational study prescribe medication . Has major surgery , ( require general anaesthesia ) within 6 week Screening visit , fully recover surgery , plan surgery Screening end study . Note : subject plan surgical procedure conduct local anaesthesia may participate . Employee Investigator study centre , direct involvement propose study study direction Investigator study centre , well family member employee Investigator . The subject unable unwilling comply fully study protocol . The subject mentally legally incapacitate . Any reason Investigator considers make subject unsuitable participate .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>